JP4628973B2 - イバブラジン塩酸塩のβｄ−結晶形態、その製造方法およびそれを含む医薬組成物 - Google Patents

イバブラジン塩酸塩のβｄ−結晶形態、その製造方法およびそれを含む医薬組成物 Download PDF

Info

Publication number
JP4628973B2
JP4628973B2 JP2006051648A JP2006051648A JP4628973B2 JP 4628973 B2 JP4628973 B2 JP 4628973B2 JP 2006051648 A JP2006051648 A JP 2006051648A JP 2006051648 A JP2006051648 A JP 2006051648A JP 4628973 B2 JP4628973 B2 JP 4628973B2
Authority
JP
Japan
Prior art keywords
ivabradine hydrochloride
expressed
crystals
ivabradine
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006051648A
Other languages
English (en)
Other versions
JP2006241155A (ja
Inventor
ステファーヌ・オルバト
マリー−ノエル・オーギュスト
ジェラール・ダミアン
Original Assignee
レ ラボラトワール セルヴィエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4628973(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by レ ラボラトワール セルヴィエ filed Critical レ ラボラトワール セルヴィエ
Publication of JP2006241155A publication Critical patent/JP2006241155A/ja
Application granted granted Critical
Publication of JP4628973B2 publication Critical patent/JP4628973B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/48—Silver or gold
    • B01J23/50—Silver
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
    • B01J23/56—Platinum group metals
    • B01J23/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
    • B01J23/56—Platinum group metals
    • B01J23/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
    • B01J23/622—Platinum group metals with gallium, indium, thallium, germanium, tin or lead with germanium, tin or lead
    • B01J23/626—Platinum group metals with gallium, indium, thallium, germanium, tin or lead with germanium, tin or lead with tin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/89—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with noble metals
    • B01J23/892—Nickel and noble metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/20—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state
    • B01J35/23—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/02—Impregnation, coating or precipitation
    • B01J37/0201—Impregnation
    • B01J37/0211—Impregnation using a colloidal suspension
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/02—Impregnation, coating or precipitation
    • B01J37/0201—Impregnation
    • B01J37/0213—Preparation of the impregnating solution
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10G—CRACKING HYDROCARBON OILS; PRODUCTION OF LIQUID HYDROCARBON MIXTURES, e.g. BY DESTRUCTIVE HYDROGENATION, OLIGOMERISATION, POLYMERISATION; RECOVERY OF HYDROCARBON OILS FROM OIL-SHALE, OIL-SAND, OR GASES; REFINING MIXTURES MAINLY CONSISTING OF HYDROCARBONS; REFORMING OF NAPHTHA; MINERAL WAXES
    • C10G45/00—Refining of hydrocarbon oils using hydrogen or hydrogen-generating compounds
    • C10G45/32—Selective hydrogenation of the diolefin or acetylene compounds
    • C10G45/34—Selective hydrogenation of the diolefin or acetylene compounds characterised by the catalyst used
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/02—Boron or aluminium; Oxides or hydroxides thereof
    • B01J21/04—Alumina
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
    • B01J23/56—Platinum group metals
    • B01J23/62—Platinum group metals with gallium, indium, thallium, germanium, tin or lead
    • B01J23/622—Platinum group metals with gallium, indium, thallium, germanium, tin or lead with germanium, tin or lead
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/89—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with noble metals
    • B01J23/8926—Copper and noble metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
    • B01J35/391—Physical properties of the active metal ingredient
    • B01J35/393—Metal or metal oxide crystallite size
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
    • B01J35/396—Distribution of the active metal ingredient
    • B01J35/397—Egg shell like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Description

本発明は、式（Ｉ）のイバブラジン塩酸塩の新規なβｄ−結晶形態、その製造方法およびそれを含む医薬組成物に関する。
Figure 0004628973
イバブラジンおよびその薬学的に許容しうる酸との付加塩、より特定的にはその塩酸塩は、非常に有益な薬理的且つ治療上の特性、特に徐脈特性を有するため、それらの化合物は、狭心症、心筋梗塞および関連する心拍障害等の心筋虚血の種々の臨床的状況の治療または予防において、さらにまた、心拍障害、特に上室性心拍障害を含む種々の症状において、および心不全において、有用である。
イバブラジンおよびその薬学的に許容しうる酸との付加塩、より特定的にはその塩酸塩の製造および治療的な使用は、欧州特許明細書ＥＰ０５３４８５９に記載されている。
この化合物の薬学的価値の観点から、それを非常に高い純度で得ることは、最も重要なことである。特に迅速な濾過および乾燥を可能にする形態で、工業的規模に簡単に転換することができる方法により、それを合成することができることも重要である。最後に、その形態は、完全に再現可能であり、簡単に製剤化され、且つ温度、光または酸素レベルについての特別な条件を伴わずに長期間保管可能なほどに十分に安定である必要がある。
特許明細書ＥＰ０５３４８５９に、イバブラジンおよびその塩酸塩の合成方法が記載されている。しかしながら、その文献には、それらの特徴を再現可能な方法で発揮する形態でイバブラジンを取得する条件が特定されていない。
ここに、出願人は、イバブラジンの特定の塩、塩酸塩を、十分に明確であって、安定性および加工性の有益な特徴を発揮する結晶形態で得ることができることを見出した。
より特定的には、本発明は、Ｘ’Ｃｅｌｅｒａｔｏｒ検出器と共にＰＡＮａｌｙｔｉｃａｌ Ｘ’Ｐｅｒｔ Ｐｒｏ回折計を用いて測定され、線位置（度で表現される、ブラッグ角２シータ）、線高さ（カウントで表現される）、線面積（カウント × 度で表現される）、ハーフハイトでの線巾（度で表現される、「ＦＷＨＭ」）および面間距離ｄ（Åで表現される）で表現された、以下の粉末Ｘ線回折図表：
Figure 0004628973
Figure 0004628973
を特徴とする、イバブラジン塩酸塩のβｄ−結晶形態に関する。
本発明は、また、イバブラジン塩酸塩および水の混合物またはイバブラジン塩酸塩、イソプロパノールおよび水の混合物を溶解が完了するまで加熱し、次いで、結晶化が完了するまで徐々に冷却し、それにより生成した結晶を回収し、脱水することを特徴とする、イバブラジン塩酸塩のβｄ−結晶形態の製造方法に関する。
・本発明に係る結晶化法において、任意の方法で得られるイバブラジン塩酸塩、例えば、特許明細書ＥＰ０５３４８５９に記載の製造方法で得られるイバブラジン塩酸塩を使用することが可能である。
・溶液には、有利には、冷却工程中に種晶を接種することができる。
本発明は、また、１以上の適切で薬学的に許容しうる不活性な非毒性賦形剤と組み合わせて、活性成分としてイバブラジン塩酸塩のβｄ−結晶形態を含む、医薬組成物に関する。本発明に係る医薬組成物の中で、より特定的には、経口、非経口（静脈内または皮下）または鼻内投与に適したもの、錠剤または糖衣錠、舌下錠、ゼラチンカプセル、甘味入り錠剤、坐剤、クリーム剤、軟膏、皮膚用ゲル剤、注射用製剤、飲用懸濁剤を挙げることができる。
有用な用量は、疾患の性質と重篤度、投与経路および患者の年齢と体重に応じて変えることができる。その用量は、１以上の投与において、一日あたり１〜５００ｍｇで変化する。
以下の実施例は、本発明を説明する。
粉末Ｘ線回折スペクトルは、以下の実験条件下に測定した。
−ＰＡＮａｌｙｔｉｃａｌ Ｘ’Ｐｅｒｔ Ｐｒｏ回折計、Ｘ’Ｃｅｌｅｒａｔｏｒ検出器、温度調節チャンバー、
−電圧４５ｋＶ、強度４０ｍＡ、
−マウンティングθ−θ、
−ニッケル（Ｋβ）フィルター、
−入射ビームおよび回折ビームＳｏｌｌｅｒスリット：０．０４ラド、
−発散スリットの固定角：１／８°、
−マスク：１０ｍｍ、
−散乱防止スリット：１／４°
−測定モード：０．０１７°づつの増加で３°から３０°まで連続して、
−ステップあたりの測定時間：１９．７秒、
−合計時間：４分３２秒、
−測定速度：０．１０８°／秒
−測定温度：周囲温度。
実施例１：イバブラジン塩酸塩のβｄ−結晶形態
精製水７２０ｍｌを５０℃に予熱し、次いで、特許明細書ＥＰ０５３４８５９中に記載の方法に従って得られたイバブラジン塩酸塩２５０ｇを攪拌しながら少しずつ加え、混合物を、溶解が完了するまで７４℃で加熱した。得られた透明な溶液を７４℃でさらに２時間加熱し、次いで、まず４０℃に、次いで周囲温度まで徐々に冷却した。溶液を引き続き周囲温度で２時間保存し、次いで、固体懸濁液を、結晶化用プレート上で薄膜に展開した。過剰の水を、窒素の穏やかな流れの下で、蒸散させた。
それにより得られた生成物は、５℃／分の速度で８０℃まで徐々に加熱することにより、脱水した。
粉末Ｘ線回折図表：
イバブラジン塩酸塩のβｄ−形態の粉末Ｘ線回折プロフィール（回折角）は、以下の表中に並べられた有意な線で与えられた。
Figure 0004628973
実施例２：医薬組成物
それぞれイバブラジンとして５ｍｇを含有する１０００錠製造用の処方：
実施例１の化合物・・・・・・・・・・・・・・・・・５．３９ｇ
トウモロコシデンプン・・・・・・・・・・・・・・・・・２０ｇ
無水コロイド状シリカ・・・・・・・・・・・・・・・・０．２ｇ
マンニトール・・・・・・・・・・・・・・・・・・６３．９１ｇ
ＰＶＰ・・・・・・・・・・・・・・・・・・・・・・・・１０ｇ
ステアリン酸マグネシウム・・・・・・・・・・・・・・０．５ｇ

Claims (6)

  1. 線位置（度で表現される、ブラッグ角２シータ）、線高さ（カウントで表現される）、線面積（カウント × 度で表現される）、ハーフハイトでの線巾（度で表現される、「ＦＷＨＭ」）および面間距離ｄ（Åで表現される）で表現された、以下の粉末Ｘ線回折図表：
    Figure 0004628973
    Figure 0004628973

    を特徴とする、式（Ｉ）：
    Figure 0004628973
    のイバブラジン塩酸塩のβｄ−結晶。
  2. イバブラジン塩酸塩および水の混合物またはイバブラジン塩酸塩、イソプロパノールおよび水の混合物を溶解が完了するまで加熱し、次いで、結晶化が完了するまで徐々に冷却し、それにより生成した結晶を回収し、次いで脱水することを特徴とする、請求項１に記載のイバブラジン塩酸塩のβｄ−結晶の製造方法。
  3. イバブラジン塩酸塩の溶液に冷却工程中にイバブラジン塩酸塩のβｄ−結晶の種晶を接種することを特徴とする、請求項２に記載の方法。
  4. １以上の薬学的に許容しうる不活性な非毒性担体と組み合わせて、活性成分として請求項１に記載のイバブラジン塩酸塩のβｄ−結晶を含む、医薬組成物。
  5. 徐脈剤として使用される医薬の製造における、請求項１に記載のイバブラジン塩酸塩のβｄ−結晶の使用。
  6. 狭心症、心筋梗塞の治療または予防において、さらにまた、上室性心拍障害において、および心不全において使用される医薬の製造における、請求項１に記載のイバブラジン塩酸塩のβｄ−結晶の使用。
JP2006051648A 2005-02-28 2006-02-28 イバブラジン塩酸塩のβｄ−結晶形態、その製造方法およびそれを含む医薬組成物 Active JP4628973B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501987A FR2882554B1 (fr) 2005-02-28 2005-02-28 Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
JP2006241155A JP2006241155A (ja) 2006-09-14
JP4628973B2 true JP4628973B2 (ja) 2011-02-09

Family

ID=34954878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006051648A Active JP4628973B2 (ja) 2005-02-28 2006-02-28 イバブラジン塩酸塩のβｄ−結晶形態、その製造方法およびそれを含む医薬組成物

Country Status (41)

Country Link
US (3) US7361652B2 (ja)
EP (1) EP1695710B1 (ja)
JP (1) JP4628973B2 (ja)
KR (1) KR100835446B1 (ja)
CN (1) CN100404512C (ja)
AP (1) AP2190A (ja)
AR (1) AR052925A1 (ja)
AT (1) ATE397449T1 (ja)
BR (1) BRPI0600795B8 (ja)
CA (1) CA2537420C (ja)
CO (1) CO5770098A1 (ja)
CR (1) CR8247A (ja)
CY (1) CY1109011T1 (ja)
DE (1) DE602006001365D1 (ja)
DK (1) DK1695710T3 (ja)
EA (1) EA008466B1 (ja)
EC (1) ECSP066374A (ja)
ES (1) ES2308690T3 (ja)
FR (1) FR2882554B1 (ja)
GE (1) GEP20084466B (ja)
GT (1) GT200600085A (ja)
HK (1) HK1096388A1 (ja)
HR (1) HRP20080418T5 (ja)
IL (1) IL173958A0 (ja)
JO (1) JO2516B1 (ja)
MA (1) MA28133A1 (ja)
MY (1) MY158127A (ja)
NO (1) NO338369B1 (ja)
NZ (1) NZ545577A (ja)
PE (1) PE20061091A1 (ja)
PL (1) PL1695710T3 (ja)
PT (1) PT1695710E (ja)
RS (1) RS50599B (ja)
SA (1) SA06270039B1 (ja)
SG (1) SG125230A1 (ja)
SI (1) SI1695710T1 (ja)
TW (1) TWI315306B (ja)
UA (1) UA80903C2 (ja)
UY (1) UY29404A1 (ja)
WO (1) WO2006092491A1 (ja)
ZA (1) ZA200601761B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7132757B2 (ja) 2018-06-12 2022-09-07 プレス工業株式会社 スライド窓保持装置

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053405A1 (de) * 2003-12-04 2005-06-16 Bayer Cropscience Aktiengesellschaft Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
US8212026B2 (en) 2007-05-30 2012-07-03 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
EP2902384B1 (en) 2010-02-12 2017-11-08 KRKA, D.D., Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
US20130084335A1 (en) 2010-06-14 2013-04-04 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2726462B1 (en) 2011-08-02 2017-03-22 Sandoz AG Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
CN107056706B (zh) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 一种用于制备盐酸伊伐布雷定α晶型的方法
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl
IT202100019967A1 (it) 2021-07-27 2023-01-27 Campagnolo Srl Dispositivo manuale di comando per bicicletta
IT202100019988A1 (it) 2021-07-27 2023-01-27 Campagnolo Srl Dispositivo manuale di comando per bicicletta

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05213890A (ja) * 1991-09-27 1993-08-24 Adir 新規（ベンゾシクロアルキル）アルキルアミン化合物
JP2005298480A (ja) * 2004-04-13 2005-10-27 Lab Servier イバブラジン及び薬学的に許容し得る酸とのその付加塩の新規合成方法
JP2006241155A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のβｄ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2006241156A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のγ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2006241157A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のγｄ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2006241154A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のβ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2007112796A (ja) * 2005-10-11 2007-05-10 Lab Servier 塩酸イバブラジンのδ結晶形態、その製造法、およびそれを含有する医薬組成物
JP2007112797A (ja) * 2005-10-11 2007-05-10 Lab Servier 塩酸イバブラジンのδｄ結晶形態、その製造法、およびそれを含有する医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05213890A (ja) * 1991-09-27 1993-08-24 Adir 新規（ベンゾシクロアルキル）アルキルアミン化合物
JP2005298480A (ja) * 2004-04-13 2005-10-27 Lab Servier イバブラジン及び薬学的に許容し得る酸とのその付加塩の新規合成方法
JP2006241155A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のβｄ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2006241156A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のγ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2006241157A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のγｄ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2006241154A (ja) * 2005-02-28 2006-09-14 Lab Servier イバブラジン塩酸塩のβ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2007112796A (ja) * 2005-10-11 2007-05-10 Lab Servier 塩酸イバブラジンのδ結晶形態、その製造法、およびそれを含有する医薬組成物
JP2007112797A (ja) * 2005-10-11 2007-05-10 Lab Servier 塩酸イバブラジンのδｄ結晶形態、その製造法、およびそれを含有する医薬組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7132757B2 (ja) 2018-06-12 2022-09-07 プレス工業株式会社 スライド窓保持装置

Also Published As

Publication number Publication date
AP2006003520A0 (en) 2006-02-28
AU2006200854A1 (en) 2006-09-14
US20060194965A1 (en) 2006-08-31
FR2882554B1 (fr) 2007-05-04
US7867995B2 (en) 2011-01-11
CO5770098A1 (es) 2007-06-29
US20080161286A1 (en) 2008-07-03
WO2006092491A1 (fr) 2006-09-08
KR20060095500A (ko) 2006-08-31
UY29404A1 (es) 2006-07-31
EA200600321A1 (ru) 2006-08-25
PL1695710T3 (pl) 2008-09-30
UA80903C2 (en) 2007-11-12
MY158127A (en) 2016-08-30
BRPI0600795A (pt) 2007-05-08
PE20061091A1 (es) 2006-11-18
TW200640874A (en) 2006-12-01
HK1096388A1 (en) 2007-06-01
TWI315306B (en) 2009-10-01
BRPI0600795B1 (pt) 2019-02-05
BRPI0600795B8 (pt) 2021-05-25
HRP20080418T3 (en) 2008-09-30
CN1827599A (zh) 2006-09-06
RS50599B (sr) 2010-05-07
DE602006001365D1 (de) 2008-07-17
KR100835446B1 (ko) 2008-06-09
PT1695710E (pt) 2008-07-21
DK1695710T3 (da) 2008-09-22
SA06270039B1 (ar) 2010-03-30
EP1695710B1 (fr) 2008-06-04
CR8247A (es) 2008-10-06
HRP20080418T5 (en) 2008-11-30
US7361652B2 (en) 2008-04-22
AP2190A (en) 2010-12-30
ES2308690T3 (es) 2008-12-01
NO20060947L (no) 2006-08-29
EP1695710A1 (fr) 2006-08-30
GT200600085A (es) 2006-10-24
EA008466B1 (ru) 2007-06-29
NZ545577A (en) 2007-01-26
SG125230A1 (en) 2006-09-29
IL173958A0 (en) 2006-07-05
JP2006241155A (ja) 2006-09-14
JO2516B1 (en) 2010-03-17
US20090318416A1 (en) 2009-12-24
NO338369B1 (no) 2016-08-15
AR052925A1 (es) 2007-04-11
MA28133A1 (fr) 2006-09-01
GEP20084466B (en) 2008-08-25
ATE397449T1 (de) 2008-06-15
CY1109011T1 (el) 2014-07-02
CN100404512C (zh) 2008-07-23
SI1695710T1 (sl) 2008-10-31
ECSP066374A (es) 2006-10-17
ZA200601761B (en) 2008-04-30
CA2537420C (fr) 2010-03-30
CA2537420A1 (fr) 2006-08-28
FR2882554A1 (fr) 2006-09-01

Similar Documents

Publication Publication Date Title
JP4628973B2 (ja) イバブラジン塩酸塩のβｄ−結晶形態、その製造方法およびそれを含む医薬組成物
JP4625776B2 (ja) イバブラジン塩酸塩のβ−結晶形態、その製造方法およびそれを含む医薬組成物
JP4628975B2 (ja) イバブラジン塩酸塩のγｄ−結晶形態、その製造方法およびそれを含む医薬組成物
JP4628974B2 (ja) イバブラジン塩酸塩のγ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2007112797A (ja) 塩酸イバブラジンのδｄ結晶形態、その製造法、およびそれを含有する医薬組成物
JP2007112796A (ja) 塩酸イバブラジンのδ結晶形態、その製造法、およびそれを含有する医薬組成物
MXPA06002274A (en) Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
MXPA06002277A (en) Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
MXPA06002276A (en) Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
MXPA06002275A (en) Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100412

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101102

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101110

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131119

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4628973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250